Tahoe Therapeutics, founded in 2022, develops computational platforms that generate and analyze large-scale biological data to understand how drugs interact with human cells. The company applies machine learning and single-cell genomics to challenges in drug discovery and cancer biology. Its leadership includes scientists and technologists from Princeton, UCSF, and UC Berkeley.
Central to its work is the Mosaic platform, which produces gigascale single-cell maps measuring drug-cell interactions. The company has used this platform to create Tahoe-100M, described as the world's largest single-cell atlas. It contains 100 million single-cell data points and 60,000 drug-patient interactions, reportedly 50 times larger than all comparable public data combined.
The company also develops foundation models for biological data. Tahoe-x1 is a 3-billion-parameter model designed to learn unified representations of genes, cells, and drugs. The model has achieved state-of-the-art performance on benchmarks relevant to cancer biology, according to the company.
